BioSpace News Archive

Lone Star Bio

Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics, Inc. today reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to ameliorate disease progression.

March 21, 2023
·
10 min read
FDA

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema

Intellia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE).

March 21, 2023
·
7 min read
Drug Development

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Sensei Biotherapeutics, Inc. today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial of SNS-101, a conditionally active VISTA-blocking antibody, in patients with solid tumors.

March 21, 2023
·
4 min read
Business

Immatics Announces Full Year 2022 Financial Results and Corporate Update

Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2022.

March 21, 2023
·
21 min read
Business

Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

Enveric Biosciences today announced that it has established Enveric Therapeutics Pty. Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic.

March 21, 2023
·
7 min read
Business

LumiraDx Reports Fourth Quarter and Full Year 2022 Results

LumiraDx Limited today announced financial results for its fourth quarter and full year ended December 31, 2022.

March 21, 2023
·
17 min read
Genetown

Inhibikase Therapeutics to Present at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders

Inhibikase Therapeutics, Inc. today announced that Milton Werner will present at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™), being held in Gothenburg, Sweden, and virtually, from March 28-April 1, 2023.

March 21, 2023
·
4 min read
Business

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that Axel Hoos, MD, PhD, has joined the NextPoint Board of Directors.

March 21, 2023
·
2 min read
Deals

Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

Berkeley Lights, Inc. (Nasdaq: BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome.

March 21, 2023
·
6 min read
Biotech Bay

ReCode Therapeutics to Present at BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines

ReCode Therapeutics today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a panel discussion titled “Novel LNPs Targeting Diverse Tissues” at 10:00 a.m. ET on Tuesday, March 28, 2023 at the virtual BMO Biopharma Spotlight Series.

March 21, 2023
·
1 min read